The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).
 
Bridget Keenan
Employment - Novo Nordisk (I)
Travel, Accommodations, Expenses - Novo Nordisk (I)
 
Madeline J Griffith
No Relationships to Disclose
 
Kelly Bauer
No Relationships to Disclose
 
Paige M. Bracci
No Relationships to Disclose
 
Spencer Behr
Honoraria - GE Healthcare
Consulting or Advisory Role - GE Healthcare (Inst)
Research Funding - GE Healthcare
 
Sarah E Umetsu
No Relationships to Disclose
 
John Dozier Gordan
Consulting or Advisory Role - Antengene
Research Funding - ShangPharma Innovation (Inst)
 
Zoe Ngo
No Relationships to Disclose
 
Syma Iqbal
Honoraria - Bristol-Myers Squibb; Celgene; Novartis
Consulting or Advisory Role - Genentech/Roche
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Novartis
Research Funding - Bayer/Onyx
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Novartis
 
Diana L. Hanna
Consulting or Advisory Role - Boehringer Ingelheim
 
Alan P. Venook
Consulting or Advisory Role - Bayer; Halozyme; Merrimack; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Serono (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Genentech; Halozyme; Roche; Taiho Pharmaceutical
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Merck; Novartis; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Merck; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca
 
Lawrence Fong
Consulting or Advisory Role - Atreca; IDEAYA Biosciences; MIODx
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Genentech/Roche; Target Pharmasolutions; Target Pharmasolutions (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Tekmira (Inst)